Highlights

  • Vitrafy Life Sciences (ASX:VFY) reported FY26 Revenue and other income of A$3.7 million, up 80% year on year.
  • The company completed a Phase II platelet study with the US Army Institute of Surgical Research.
  • Vitrafy reported A$41.2 million in cash and term deposits at FY26 year end.
  • The company is progressing US expansion, Manufacturing activities and regulatory milestones for FY27.

Vitrafy Life Sciences (ASX:VFY) is advancing its biopreservation technology platform following FY26 operational progress, US Partnership expansion and clinical validation activities. The company is focused on commercialising its preservation solutions across blood, cell and gene therapy and other healthcare applications.

What happened

Vitrafy released its FY26 preliminary final report on 4 August 2026, highlighting revenue growth, reduced statutory losses and progress across its technology platform.

Revenue and other income increased to A$3.7 million, up 80% compared with FY25.

The company reported a net loss after tax attributable to owners of A$16.2 million, improving from a loss of A$32.7 million in FY25.

Vitrafy completed a Phase II in-vitro platelet study with the US Army Institute of Surgical Research across 20 donors using commercial-scale volumes.

The study recorded mean post-thaw, no-wash platelet recovery of 94.4%, compared with US fresh platelet guidelines of 75% and European standards of 50%.

The company also expanded its US blood-market partnerships, including agreements with Vitalant and Hoxworth Blood Center.

The Hoxworth agreement involves deployment of Vitrafy’s cryopreservation ecosystem across seven collection sites in the United States.

Vitrafy is also progressing US operational expansion, including a customer demonstration site, additional US employees and plans for US manufacturing during FY27.

The numbers investors need to know

Vitrafy’s FY26 financial performance reflected continued Investment in commercialisation activities.

Revenue and other income reached A$3.7 million, while product sales revenue was A$169,000, representing growth from the previous year.

Contracted revenue from blood partnerships across FY26 and FY27 is approximately A$1.0 million.

Operating loss was A$16.8 million compared with A$14.6 million in FY25.

The company finished FY26 with A$41.2 million in cash and term deposits following a A$30 million Capital raising, with a further A$2 million received after the reporting period.

Vitrafy manufactured 10 Guardion freezing units during FY26, with additional units planned for FY27.

The company expects 15 additional Guardion units to be delivered during the first half of FY27, including three units allocated for blood partners.

The LifeChain sample-tracking software has been developed to 21 CFR Part 11 standards, with validation progressing towards an FDA Class 2 510(k) exempt listing targeted for the first half of FY27.

Business outlook and key considerations

Vitrafy’s focus remains converting technology validation and partnerships into commercial revenue.

The company is progressing activities across three key areas: blood preservation, cell and gene therapy and animal health applications.

Key FY27 milestones include US manufacturing commencement, additional Guardion deployments, regulatory progress and conversion of partnerships into revenue-generating customer relationships.

The company’s commercial progress will depend on customer adoption, regulatory timelines and scaling manufacturing capability.

Bull case

Vitrafy has demonstrated technical progress through its platelet preservation study with the US Army Institute of Surgical Research and established partnerships across the blood collection sector.

The company’s blood-market partnerships provide exposure to approximately 132 US collection sites, representing around 13% of registered US locations.

The Guardion platform, LifeChain software and regulatory development pathway provide multiple components for a broader commercial ecosystem.

A growing partnership base combined with US manufacturing capability could support future revenue expansion.

Bear case and risks

Vitrafy remains at an early commercialisation stage, with limited current product revenue compared with operating costs.

Product sales revenue of A$169,000 remains small relative to the A$16.8 million operating loss, meaning future valuation depends on successful commercial conversion.

Human health device placements currently do not generate revenue, and pilot deployments may not automatically translate into larger customer orders.

Additional risks include regulatory timing, manufacturing execution, healthcare customer adoption cycles, ongoing cash utilisation and future funding requirements.

What comes next

The key FY27 milestones include FDA Class 2 510(k) exempt listing progress, commencement of US manufacturing, delivery of additional Guardion units and further blood partner deployments.

Investors will also monitor conversion of existing partnerships into revenue-generating contracts, expansion into cell and gene therapy applications and further commercial agreements.

Conclusion

Vitrafy Life Sciences (ASX:VFY) enters FY27 with technical validation, expanding healthcare partnerships and a strengthened balance sheet.

The company has progressed its preservation technology platform through clinical studies, customer relationships and operational expansion. The next phase will depend on converting these developments into commercial revenue and demonstrating scalable adoption across healthcare markets.